<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214097</url>
  </required_header>
  <id_info>
    <org_study_id>RO02803</org_study_id>
    <secondary_id>NCI (P01 CA88960)</secondary_id>
    <secondary_id>2002-322</secondary_id>
    <secondary_id>A533300</secondary_id>
    <secondary_id>SMPH/HUMAN ONCOLOGY</secondary_id>
    <nct_id>NCT00214097</nct_id>
  </id_info>
  <brief_title>Phase I/II Hypofractionated Radiotherapy for Prostate Cancer</brief_title>
  <official_title>Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the clinical feasibility of using Intensity-modulated
      radiation therapy (IMRT) combined with daily pretreatment prostate localization to deliver
      increasingly hypofractionated treatment courses. Progressively larger fraction sizes will be
      delivered in a phase I design based on both acute and long-term tolerances to the treatment.
      The dose-per-fraction escalation design utilizes schemas that maintain an isoeffective dose
      for late effects, while predicting that tumor control will actually improve. The delivery of
      fewer, larger fractions of radiation, if proven effective and safe, would result in
      significant cost saving and more efficient use of resources. Phase II will commence with
      Maximum Tolerated Dose (MTD) finding with up to 200 additional patients being enrolled during
      this phase of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2002</start_date>
  <completion_date type="Actual">August 21, 2017</completion_date>
  <primary_completion_date type="Actual">August 21, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>dose escalation, 3 possible dose groups, with one Phase II group based on MTD.
Per protocol, while waiting for safety data to mature for escalation, protocol permitted enrollment to continue on last dose that was already proven safe. Thus Arms one and two have more than 50 subjects each.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experience Grade 3 or Higher Acute Toxicities</measure>
    <time_frame>90 days post radiation treatment</time_frame>
    <description>To evaluate acute tolerances to dose-per-fraction escalation in the treatment of prostate cancer using optimized treatment of Intensity-modulated radiation therapy (IMRT), daily rectal balloon displacement, and transabdominal ultrasound localization of the prostate. For toxicities observed within the first 10 patients at each hypofractionation level, ≥20% acute grade 3 or higher GI or genitourinary (GU) toxicity will constitute a threshold toxicity level and will dictate a decrease in frequency of treatment by one treatment per week. Maximum tolerated dose is reached if 20% of participants experience acute toxicities grade 3 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Grade 2 or Higher Late Rectal Toxicities at Any Time During Follow Up</measure>
    <time_frame>from 90 days post XRT through last follow-up visit (up to 3 years)</time_frame>
    <description>To evaluate late radiation toxicities to dose-per fraction escalation in the treatment of prostate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Progression-free Survival Based on PSA Surveillance</measure>
    <time_frame>up to 15 years from enrollment</time_frame>
    <description>Patients will be considered to be without biochemical recurrence if either the Prostate-specific antigen (PSA) is still declining or the PSA nadir has been reached and is below 1.0ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fox Chase Bowel Survey at Baseline and 3 Years</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>The Fox Chase Bowel/Bladder survey was divided into two sections: Bowel (questions 1 to 14, N=14) and Bladder (questions 19, and 21 to 30, N=11). To facilitate analysis, Bowel and Bladder scores for each section were rescaled to a total score of between 0 - 100, where higher scores indicated better Quality of Life (QoL). Results for the Bowel Section are reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fox Chase Bladder Survey at Baseline and 3 Years</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>The Fox Chase Bowel/Bladder survey was divided into two sections: Bowel (questions 1 to 14, N=14) and Bladder (questions 19, and 21 to 30, N=11). To facilitate analysis, Bowel and Bladder scores for each section were rescaled to a total score of between 0 - 100, where higher scores indicated better Quality of Life. Results for the Bladder Section are reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF) Score at Baseline and 3 Years</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>The IIEF is a 15-item survey where 9-items are scored 0-5 and 6-items are scored 1-5 with a total range of 6-75. The standard scoring mechanism was used for IIEF, where the QoL items corresponded to the following domains: erectile function (score range 1-30), orgasmic function (score range 1-10), sexual desire (score range 2-10), intercourse satisfaction (score range 0-15), and overall satisfaction (score range 2-10). Higher numbers indicate increased QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spritzer Quality of Life Index (SQLI) at Baseline and 3 Years</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>The SQLI is composed of five items (activity, daily living, health, support, outlook) scored utilizing a numerical scale of 0-2. Standard scoring was also used for the SQLI survey (total score range 0-10) where higher score indicate increased QoL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>64.7 Gy/22 fractions of 2.94 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>58.08 Gy/16 fractions of 3.63 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>51.6 Gy/12 fractions of 4.3 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Daily radiation to prescribed dose</description>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_label>Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically proven adenocarcinoma of the prostate.

          -  Stage ≤ T2b disease, as defined by 1997 American Joint Committee on Cancer (AJCC)
             classification

          -  Predicted risk of lymph node involvement (by standard nomograms) of 15% or less (24),
             OR histologically negative pelvic nodes

          -  Gleason score ≤ 7

          -  No evidence of distant metastasis

          -  Age 18+

          -  Informed consent signed in accordance with institutional protocol

          -  Pretreatment evaluations must be completed as specified in Section 7.0.

          -  ECOG performance status 0-1

          -  No previous or concurrent cancers, other than localized basal cell or squamous cell
             skin carcinoma, unless continually disease free for at least 5 years

          -  No prior pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy

          -  Gonadotropin-releasing hormone agonist (GnRH-a) use permitted (maximum of 6 months
             duration). Anti-androgen therapy permitted concurrently with GnRH-a.

          -  No previous or concurrent cytotoxic chemotherapy

          -  No radical surgery or cryosurgery for prostate cancer

          -  The absence of any co-morbid medical condition which would constitute a
             contraindication for radical radiotherapy

          -  The absence of serious concurrent illness of psychological, familial, sociological,
             geographical or other concomitant conditions which do not permit adequate follow-up
             and compliance with the study protocol.

          -  No current use of anticoagulation therapy, other than aspirin.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ritter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cancer.wisc.edu/</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <results_reference>
    <citation>Brower JV, Forman JD, Kupelian PA, Petereit DG, Gondi V, Lawton CA, Anger N, Saha S, Chappell R, Ritter MA. Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. Radiother Oncol. 2016 Jan;118(1):99-104. doi: 10.1016/j.radonc.2015.12.018. Epub 2016 Jan 2.</citation>
    <PMID>26755165</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>May 22, 2019</results_first_submitted>
  <results_first_submitted_qc>September 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2006</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT00214097/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Level 1</title>
          <description>2.94 gy/fr, 22 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="P2">
          <title>Level 2</title>
          <description>3.63 gy/fr, 16 fractions, 50 patients first 10 treated with 4 fractions per week next 40 treated with 5 fractions per week
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="P3">
          <title>Level 3</title>
          <description>4.3 gy/fr, 12 fractions, 50 patients first 10 treated with 4 fractions per week next 40 treated with 5 fractions per week
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101">Escalation to the next higher level will occur when &gt; 20 pt yrs of F/U and &gt; 5 pts followed &gt;1 yr</participants>
                <participants group_id="P2" count="111">Escalation to the next higher level will occur when &gt; 20 pt yrs of F/U and &gt; 5 pts followed &gt;1 yr</participants>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Level I</title>
          <description>2.94 gy/fr, 22 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="B2">
          <title>Level II</title>
          <description>3.63 gy/fr, 16 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="B3">
          <title>Level III</title>
          <description>4.3 gy/fr, 12 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="347"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="47" upper_limit="83"/>
                    <measurement group_id="B2" value="67" lower_limit="45" upper_limit="81"/>
                    <measurement group_id="B3" value="68" lower_limit="52" upper_limit="85"/>
                    <measurement group_id="B4" value="68" lower_limit="45" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience Grade 3 or Higher Acute Toxicities</title>
        <description>To evaluate acute tolerances to dose-per-fraction escalation in the treatment of prostate cancer using optimized treatment of Intensity-modulated radiation therapy (IMRT), daily rectal balloon displacement, and transabdominal ultrasound localization of the prostate. For toxicities observed within the first 10 patients at each hypofractionation level, ≥20% acute grade 3 or higher GI or genitourinary (GU) toxicity will constitute a threshold toxicity level and will dictate a decrease in frequency of treatment by one treatment per week. Maximum tolerated dose is reached if 20% of participants experience acute toxicities grade 3 or higher.</description>
        <time_frame>90 days post radiation treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Level 1</title>
            <description>2.94 gy/fr, 22 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level 2</title>
            <description>3.63 gy/fr, 16 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level 3</title>
            <description>4.3 gy/fr, 12 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Grade 3 or Higher Acute Toxicities</title>
          <description>To evaluate acute tolerances to dose-per-fraction escalation in the treatment of prostate cancer using optimized treatment of Intensity-modulated radiation therapy (IMRT), daily rectal balloon displacement, and transabdominal ultrasound localization of the prostate. For toxicities observed within the first 10 patients at each hypofractionation level, ≥20% acute grade 3 or higher GI or genitourinary (GU) toxicity will constitute a threshold toxicity level and will dictate a decrease in frequency of treatment by one treatment per week. Maximum tolerated dose is reached if 20% of participants experience acute toxicities grade 3 or higher.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing Grade 2 or Higher Late Rectal Toxicities at Any Time During Follow Up</title>
        <description>To evaluate late radiation toxicities to dose-per fraction escalation in the treatment of prostate</description>
        <time_frame>from 90 days post XRT through last follow-up visit (up to 3 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Level I</title>
            <description>2.94 gy/fr, 22 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level II</title>
            <description>3.63 gy/fr, 16 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level III</title>
            <description>4.3 gy/fr, 12 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Grade 2 or Higher Late Rectal Toxicities at Any Time During Follow Up</title>
          <description>To evaluate late radiation toxicities to dose-per fraction escalation in the treatment of prostate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Progression-free Survival Based on PSA Surveillance</title>
        <description>Patients will be considered to be without biochemical recurrence if either the Prostate-specific antigen (PSA) is still declining or the PSA nadir has been reached and is below 1.0ng/ml</description>
        <time_frame>up to 15 years from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Level I</title>
            <description>2.94 gy/fr, 22 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level II</title>
            <description>3.63 gy/fr, 16 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level III</title>
            <description>4.3 gy/fr, 12 fractions,
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Progression-free Survival Based on PSA Surveillance</title>
          <description>Patients will be considered to be without biochemical recurrence if either the Prostate-specific antigen (PSA) is still declining or the PSA nadir has been reached and is below 1.0ng/ml</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" lower_limit="88.2" upper_limit="94.8"/>
                    <measurement group_id="O2" value="92.7" lower_limit="90" upper_limit="95.4"/>
                    <measurement group_id="O3" value="94.1" lower_limit="91.9" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fox Chase Bowel Survey at Baseline and 3 Years</title>
        <description>The Fox Chase Bowel/Bladder survey was divided into two sections: Bowel (questions 1 to 14, N=14) and Bladder (questions 19, and 21 to 30, N=11). To facilitate analysis, Bowel and Bladder scores for each section were rescaled to a total score of between 0 - 100, where higher scores indicated better Quality of Life (QoL). Results for the Bowel Section are reported here.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Level I</title>
            <description>2.94 gy/fr, 22 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level II</title>
            <description>3.63 gy/fr, 16 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level III</title>
            <description>4.3 gy/fr, 12 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Fox Chase Bowel Survey at Baseline and 3 Years</title>
          <description>The Fox Chase Bowel/Bladder survey was divided into two sections: Bowel (questions 1 to 14, N=14) and Bladder (questions 19, and 21 to 30, N=11). To facilitate analysis, Bowel and Bladder scores for each section were rescaled to a total score of between 0 - 100, where higher scores indicated better Quality of Life (QoL). Results for the Bowel Section are reported here.</description>
          <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" spread="10.7"/>
                    <measurement group_id="O2" value="88.0" spread="14.6"/>
                    <measurement group_id="O3" value="86.2" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" spread="11.1"/>
                    <measurement group_id="O2" value="87.7" spread="11.6"/>
                    <measurement group_id="O3" value="85.4" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fox Chase Bladder Survey at Baseline and 3 Years</title>
        <description>The Fox Chase Bowel/Bladder survey was divided into two sections: Bowel (questions 1 to 14, N=14) and Bladder (questions 19, and 21 to 30, N=11). To facilitate analysis, Bowel and Bladder scores for each section were rescaled to a total score of between 0 - 100, where higher scores indicated better Quality of Life. Results for the Bladder Section are reported here.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Level I</title>
            <description>2.94 gy/fr, 22 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level II</title>
            <description>3.63 gy/fr, 16 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level III</title>
            <description>4.3 gy/fr, 12 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Fox Chase Bladder Survey at Baseline and 3 Years</title>
          <description>The Fox Chase Bowel/Bladder survey was divided into two sections: Bowel (questions 1 to 14, N=14) and Bladder (questions 19, and 21 to 30, N=11). To facilitate analysis, Bowel and Bladder scores for each section were rescaled to a total score of between 0 - 100, where higher scores indicated better Quality of Life. Results for the Bladder Section are reported here.</description>
          <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="9.4"/>
                    <measurement group_id="O2" value="84.7" spread="10.1"/>
                    <measurement group_id="O3" value="82.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="13.5"/>
                    <measurement group_id="O2" value="82.5" spread="10.1"/>
                    <measurement group_id="O3" value="81.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF) Score at Baseline and 3 Years</title>
        <description>The IIEF is a 15-item survey where 9-items are scored 0-5 and 6-items are scored 1-5 with a total range of 6-75. The standard scoring mechanism was used for IIEF, where the QoL items corresponded to the following domains: erectile function (score range 1-30), orgasmic function (score range 1-10), sexual desire (score range 2-10), intercourse satisfaction (score range 0-15), and overall satisfaction (score range 2-10). Higher numbers indicate increased QoL.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Level I</title>
            <description>2.94 gy/fr, 22 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level II</title>
            <description>3.63 gy/fr, 16 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level III</title>
            <description>4.3 gy/fr, 12 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF) Score at Baseline and 3 Years</title>
          <description>The IIEF is a 15-item survey where 9-items are scored 0-5 and 6-items are scored 1-5 with a total range of 6-75. The standard scoring mechanism was used for IIEF, where the QoL items corresponded to the following domains: erectile function (score range 1-30), orgasmic function (score range 1-10), sexual desire (score range 2-10), intercourse satisfaction (score range 0-15), and overall satisfaction (score range 2-10). Higher numbers indicate increased QoL.</description>
          <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="11.7"/>
                    <measurement group_id="O2" value="17.6" spread="11.7"/>
                    <measurement group_id="O3" value="15.1" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="10.6"/>
                    <measurement group_id="O2" value="13.6" spread="11.7"/>
                    <measurement group_id="O3" value="9.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spritzer Quality of Life Index (SQLI) at Baseline and 3 Years</title>
        <description>The SQLI is composed of five items (activity, daily living, health, support, outlook) scored utilizing a numerical scale of 0-2. Standard scoring was also used for the SQLI survey (total score range 0-10) where higher score indicate increased QoL.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Level I</title>
            <description>2.94 gy/fr, 22 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O2">
            <title>Level II</title>
            <description>3.63 gy/fr, 16 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
          <group group_id="O3">
            <title>Level III</title>
            <description>4.3 gy/fr, 12 fractions
Radiotherapy: Daily radiation to prescribed dose</description>
          </group>
        </group_list>
        <measure>
          <title>Spritzer Quality of Life Index (SQLI) at Baseline and 3 Years</title>
          <description>The SQLI is composed of five items (activity, daily living, health, support, outlook) scored utilizing a numerical scale of 0-2. Standard scoring was also used for the SQLI survey (total score range 0-10) where higher score indicate increased QoL.</description>
          <population>Unavailable quality of life questionnaires at year 3. All mean scores were adjusted for missing data. The missing data for questionnaires were handled by weighted mean imputation. Cases with more than half of the total questions missing were not included.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="0.7"/>
                    <measurement group_id="O2" value="9.4" spread="1.2"/>
                    <measurement group_id="O3" value="9.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="1.4"/>
                    <measurement group_id="O2" value="9.8" spread="0.4"/>
                    <measurement group_id="O3" value="9.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Acute GI and GU toxicities and Late GI and GU toxicities were recorded for the duration of the study. For level 1 patients, median followup was 100 months, for level 2 patients median follow up was 85.5 months and for level 3 it was 61.7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Level 1</title>
          <description>2.94 gy/fr, 22 fractions, minimum 50 patients to escalate, (back filling permitted while next dose level data matures for escalation) first 10 treated with 4 fractions per week next 40 + treated with 5 fractions per week
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="E2">
          <title>Level 2</title>
          <description>3.63 gy/fr, 16 fractions, minimum 50 patients ( back filling permitted while next dose level data matures for escalation) first 10 treated with 4 fractions per week next 40 + treated with 5 fractions per week
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
        <group group_id="E3">
          <title>Level 3</title>
          <description>4.3 gy/fr, 12 fractions, 50 patients, for safety, up to an additional 100 for phase II component of study first 10 treated with 4 fractions per week next 40 +treated with 5 fractions per week
Radiotherapy: Daily radiation to prescribed dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GI</sub_title>
                <description>modified RTOG grading criteria</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GU</sub_title>
                <description>RTOG modified grading criteria</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="101"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="111"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Late GI and GU toxicities</sub_title>
                <description>FC-LENT grading criteria</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="111"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Diana Trask</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-9528</phone>
      <email>trask@humonc.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

